SNYR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Synergy CHC Corp (SNYR) is not a strong buy for a beginner, long-term investor at this time. While the stock is oversold and has potential upside based on the analyst price target, the weak financial performance, lack of recent positive news, and bearish technical indicators suggest it is better to hold off on investing until clearer positive signals emerge.
The stock is currently in a bearish trend with moving averages showing SMA_200 > SMA_20 > SMA_5. The RSI of 17.909 indicates the stock is oversold, but the MACD histogram is negative and contracting, signaling weak momentum. Key support levels are at 1.344 and 1.238, with resistance at 1.688 and 1.794.
An analyst recently initiated coverage with a Buy rating and a $5 price target, citing large market opportunities for the company's brain health supplement FOCUSfactor.
The company's financial performance in Q3 2025 showed a significant decline in net income (-84.01% YoY) and EPS (-90.00% YoY), despite a 12.40% increase in revenue. Gross margin improvement is positive but insufficient to offset the earnings decline. No recent news or significant trading trends from hedge funds, insiders, or Congress.
In Q3 2025, revenue increased by 12.40% YoY to $8,010,112, but net income dropped by 84.01% YoY to $125,327, and EPS fell by 90.00% YoY to 0.01. Gross margin improved to 70.5%, up 5.62% YoY.
Ascendiant analyst Edward Woo initiated coverage with a Buy rating and a $5 price target, citing large market opportunities for the company's brain health supplement FOCUSfactor.
